GUIDELINES
Rheumatoid arthritis
Online publication date: 2016-10-11
Reumatologia 2016;(Aktualizacja zaleceń postępowania diagnostyczno-terapeutycznego w chorobach reumatycznych na podstawie rekomendacji EULAR/ACR 1):4-11
REFERENCES (16)
1.
Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid Arthritis Classification Criteria. An American College of Rheumatology/ European Leagne Against Rheumatism Collaborative Initiative. Arthritis Rheum 2010; 62: 2569-2581.
2.
Machado P, Castrejon I, Katchamart W, et al. Multinational evidence-based recommendations on how to investigate and follow-up undifferentiated peripheral inflammatory arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2011; 70: 15-24.
3.
Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease – modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73: 492-509.
4.
Smolen J S, Aletaha D, Bijlsma JWJ, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-637.
5.
Felson D, Smolen J, Wells G, et al. American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trial. Ann Rheum Dis 2011; 70: 404-413.
6.
Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease – modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-975.
7.
Visser K, Katchamart W, Losa E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion in the broad international panel of the rheumatologists in the 3D initiative. Ann Rheum Dis 2009; 68: 1086-1093.
8.
Van der Maas A, Kievit W, van der Bernt BJ, et al. Down titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Ann Rheum Dis 2012; 71: 1849-1845.
9.
Klarenbeek NB, van der Kooij SM, Guler-Yuksel M, et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the Best-study. Ann Rheum Dis 2011; 70: 315-319.
10.
Kavanaugh A, Fleischmann RM, Emery P, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26 week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013; 72: 64-71.
11.
Smolen JS, Nash P, Durez P, et al. Maintenance, reduction or withdrawal of etanercept after treatment with etanercept and methotrexate in patiens with moderate rheumatoid arthrtis (PRESERVE): a randomised controlled trial. Lancet 2013; 381: 918-929.
12.
Van Vollenhoven RF, Ostergaard M, Leirisalo-Repo M, et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis 2016; 75: 52-58.
13.
Tanaka Y, Hirata S, Kubo S, et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1 year outcome of the HONOR study. Ann Rheum Dis 2015; 74: 380-395.
14.
Aquilar-Lozano L, Castillo-Ortiz JD, Vargas-Serafin C, et al. Sustained clinical remission and rate of relapse after tocilizumab withdrawal in patients with rheumatoid arthritis. J Rheumatol 2013; 40: 1069-1073.
15.
Takeuchi T, Matsubara T, Ohta S, et al. Abatacept biologic free remission study in estabished rhematoid arthritis patients. ORION study. Arthritis Rheum 2012; 64: S552.
16.
Nagy G, van Vollenhoven RF. Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now. Arthritis Res Ther 2015; 17: 181-185.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
